Mechanism of action
Quetiapine exerts its therapeutic effects through antagonism at multiple central nervous system receptors. Its antipsychotic activity is primarily mediated by antagonism at serotonin 5-HT2A receptors and dopamine D2 receptors in the mesolimbic and mesocortical pathways. The 5-HT2A/D2 antagonism ratio is higher than typical antipsychotics, contributing to its atypical profile with reduced extrapyramidal symptoms.
Quetiapine also blocks histamine H1 receptors (very high affinity), α1-adrenergic receptors, and α2-adrenergic receptors. The strong H1 antagonism accounts for its pronounced sedative effects and contributes to weight gain and metabolic disturbances. Alpha-1 blockade causes orthostatic hypotension, particularly during dose titration.
The active metabolite norquetiapine (N-desalkylquetiapine) contributes to the antidepressant effects through norepinephrine reuptake inhibition and partial agonism at 5-HT1A receptors. This metabolite may explain quetiapine's efficacy in bipolar depression and as augmentation in major depressive disorder. Unlike many other antipsychotics, quetiapine has relatively low D2 receptor occupancy at clinical doses, which may reduce the risk of extrapyramidal symptoms and hyperprolactinemia.
- Quetiapine is an atypical antipsychotic with antagonism at 5-HT2A, D2, H1, and α1-adrenergic receptors
- Active metabolite norquetiapine inhibits norepinephrine reuptake and contributes to antidepressant effects
- High risk for metabolic syndrome: weight gain, hyperglycemia, dyslipidemia—requires monitoring
- Causes minimal prolactin elevation and low EPS risk due to rapid D2 receptor dissociation
- Black box warning: increased mortality in elderly patients with dementia-related psychosis
- Metabolized primarily by CYP3A4; strong inhibitors require dose reduction, inducers reduce efficacy
- Sedation and orthostatic hypotension are very common, especially during initiation (H1 and α1 antagonism)
- FDA-approved for schizophrenia, bipolar disorder (mania and depression), and adjunctive treatment in major depression
Indications
Quetiapine is FDA-approved for several psychiatric conditions:
Schizophrenia: Used for acute treatment and maintenance of schizophrenia in adults and adolescents aged 13-17 years. Effective for positive symptoms (hallucinations, delusions) and negative symptoms (flat affect, social withdrawal).
Bipolar disorder: Approved for acute manic episodes, acute depressive episodes, and maintenance treatment as monotherapy or adjunct to lithium or valproate. Both immediate-release and extended-release formulations are effective for bipolar depression, distinguishing quetiapine from many other antipsychotics.
Major depressive disorder (adjunctive): Extended-release quetiapine is approved as adjunctive therapy to antidepressants for treatment-resistant major depression.
Off-label uses
- Generalized anxiety disorder
- Insomnia (low doses, though not recommended as first-line)
- Post-traumatic stress disorder
- Delirium (particularly in hospitalized patients)
- Behavioral disturbances in dementia (carries black box warning)
Dosing follows the product label and varies significantly by indication, with extended-release formulations typically administered once daily.
Pharmacokinetics
Absorption: Quetiapine is rapidly absorbed after oral administration, with peak plasma concentrations reached in approximately 1.5 hours. Food increases absorption, particularly high-fat meals. Bioavailability is approximately 100% due to extensive first-pass metabolism.
Distribution: Highly protein-bound (83%), with a large volume of distribution. Quetiapine crosses the blood-brain barrier readily to reach CNS targets.
Metabolism: Extensively metabolized in the liver primarily via CYP3A4, with minor contribution from CYP2D6. The major active metabolite is norquetiapine (N-desalkylquetiapine), which has a longer half-life than the parent drug and contributes to therapeutic effects. Genetic polymorphisms in CYP2D6 have minimal clinical impact due to the predominance of CYP3A4 metabolism.
Excretion: Elimination half-life is approximately 6 hours for immediate-release and 7 hours for extended-release formulations. Norquetiapine has a half-life of 12 hours. Less than 5% is excreted unchanged in urine; most metabolites are eliminated in urine and feces. Clearance is reduced by approximately 25% in elderly patients and 25-30% in patients with severe renal impairment, though dose adjustment is generally not required.
Adverse effects
Quetiapine causes several characteristic adverse effects related to its receptor antagonism profile:
Common adverse effects
- Somnolence and sedation: Very common, especially during initiation, due to H1 antagonism
- Orthostatic hypotension and dizziness: Related to α1-adrenergic blockade, particularly during dose titration
- Dry mouth: Anticholinergic effect
- Constipation: Anticholinergic effect
- Weight gain: Significant concern, related to H1 and 5-HT2C antagonism
- Tachycardia: Compensatory response to hypotension
Metabolic effects
Quetiapine carries significant risk for metabolic syndrome, including:
- Hyperglycemia and new-onset diabetes mellitus
- Dyslipidemia (elevated triglycerides and LDL cholesterol)
- Weight gain (average 2-4 kg, but highly variable)
Baseline and periodic monitoring of fasting glucose, lipid panel, weight, and BMI is recommended.
Serious adverse effects
- QTc prolongation: Dose-related risk of cardiac arrhythmias
- Cataracts: Observed in animal studies; regular ophthalmologic examination debated
- Neuroleptic malignant syndrome: Rare but life-threatening (fever, rigidity, altered mental status, autonomic instability)
- Tardive dyskinesia: Lower risk than typical antipsychotics but still possible with chronic use
- Seizures: Dose-dependent risk, particularly at higher doses
- Hypothyroidism: Dose-related decrease in thyroid hormones, monitor TSH
- Leukopenia, neutropenia, agranulocytosis: Rare but serious hematologic effects
Extrapyramidal symptoms
Quetiapine has a relatively low incidence of EPS compared to typical antipsychotics and some other atypicals, due to lower D2 occupancy and rapid dissociation from D2 receptors. However, akathisia, dystonia, and parkinsonism can still occur, particularly at higher doses.
Hyperprolactinemia
Unlike many other antipsychotics, quetiapine causes minimal prolactin elevation due to its rapid dissociation from D2 receptors in the tuberoinfundibular pathway. This makes it a preferred option when prolactin-related side effects (galactorrhea, sexual dysfunction, menstrual irregularities) are a concern.
Contraindications and warnings
Absolute contraindications
- Known hypersensitivity to quetiapine or any component of the formulation
Black box warnings
Increased mortality in elderly patients with dementia-related psychosis: All antipsychotics, including quetiapine, carry a black box warning for increased risk of death (primarily cardiovascular or infectious causes) in elderly patients with dementia. Quetiapine is not approved for this indication.
Suicidal thoughts and behaviors: Increased risk in children, adolescents, and young adults (under age 24) with major depressive disorder and other psychiatric disorders. Close monitoring is required, especially during initial treatment and dose changes.
Warnings and precautions
- Cardiovascular disease: Use with caution in patients with history of myocardial infarction, heart failure, arrhythmias, or QTc prolongation. Obtain baseline and periodic ECG in at-risk patients.
- Cerebrovascular events: Increased risk of stroke in elderly patients with dementia.
- Seizure disorder: Lowers seizure threshold; use cautiously in patients with history of seizures.
- Hepatic impairment: Dose reduction may be necessary; quetiapine is extensively metabolized by the liver.
- Aspiration pneumonia: Risk increased due to sedation and esophageal dysmotility.
- Hypotension: Use caution in patients taking antihypertensives or with conditions predisposing to hypotension.
- Suicide risk: Monitor closely, particularly during initiation and dose changes.
Pregnancy and lactation
Pregnancy category C (former FDA classification). Quetiapine crosses the placenta. Third-trimester exposure is associated with risk of extrapyramidal symptoms and withdrawal in neonates. Use only if potential benefit justifies risk. Quetiapine is excreted in breast milk; breastfeeding is generally not recommended during treatment.
Drug interactions
Quetiapine undergoes significant drug interactions due to CYP3A4 metabolism and its CNS depressant effects.
CYP3A4 inhibitors
Strong CYP3A4 inhibitors significantly increase quetiapine plasma concentrations:
- Azole antifungals (ketoconazole, itraconazole)
- Macrolide antibiotics (erythromycin, clarithromycin)
- Protease inhibitors (ritonavir, indinavir)
- Grapefruit juice
Dose reduction of quetiapine is required when co-administered with potent CYP3A4 inhibitors.
CYP3A4 inducers
Strong CYP3A4 inducers decrease quetiapine concentrations, potentially reducing efficacy:
- Carbamazepine: May reduce quetiapine levels by up to 90%
- Phenytoin
- Rifampin
- St. John's wort
Higher doses of quetiapine may be necessary; consider alternative agents.
CNS depressants
Additive sedation and respiratory depression risk:
- Benzodiazepines
- Opioids
- Alcohol
- Other sedating medications (first-generation antihistamines, barbiturates)
QTc-prolonging agents
Increased risk of cardiac arrhythmias:
- Class IA and III antiarrhythmics
- Other antipsychotics
- Certain antibiotics (fluoroquinolones, macrolides)
- Methadone
Antihypertensives
Quetiapine may enhance hypotensive effects due to α1-blockade.
Dopamine agonists and levodopa
Quetiapine may antagonize the effects of dopaminergic agents used in Parkinson disease, though it is sometimes used cautiously for psychosis in this population due to relatively lower D2 affinity.
Clinical pearls
- Low-dose quetiapine for insomnia: Although commonly prescribed off-label at doses of 25-100 mg for sleep, this practice is not evidence-based and exposes patients to metabolic and other risks without proven long-term benefit for primary insomnia.
- Metabolic monitoring is mandatory: Check fasting glucose, lipid panel, weight, and waist circumference at baseline, 12 weeks, and then annually. Screen for diabetes symptoms. Quetiapine ranks among the highest risk atypical antipsychotics for metabolic syndrome.
- Dose titration reduces orthostatic hypotension: Starting at low doses and titrating gradually minimizes risk of dizziness, falls, and syncope, particularly in elderly patients.
- Extended-release vs. immediate-release: Extended-release formulations allow once-daily dosing (typically at bedtime) and may have slightly different side effect profiles. They are not interchangeable mg-for-mg with immediate-release.
- Minimal prolactin elevation: Unlike risperidone or paliperidone, quetiapine rarely causes hyperprolactinemia, making it a good choice when avoiding prolactin-related side effects is important (sexual dysfunction, galactorrhea, bone density concerns).
- Rapid D2 dissociation: Quetiapine binds and dissociates rapidly from D2 receptors ("hit-and-run" binding), contributing to low EPS risk and minimal prolactin elevation, but may reduce efficacy for severe agitation compared to tighter-binding agents.
- Withdrawal and rebound: Abrupt discontinuation can cause withdrawal symptoms including nausea, vomiting, insomnia, and rebound psychosis. Taper gradually when discontinuing.
- Not a controlled substance: Unlike benzodiazepines, quetiapine is not a scheduled drug, but there are reports of misuse for sedation, particularly in institutional settings.
- Thyroid monitoring: Quetiapine can cause dose-related decreases in total and free T4 and T3. Check baseline TSH and monitor periodically.
- Cataract screening: Based on animal data showing lens changes, some guidelines recommend baseline and periodic slit-lamp examinations, though clinical significance in humans remains unclear.
Practice questions
1. A 28-year-old woman with bipolar I disorder is started on quetiapine for an acute manic episode. Four weeks later, she returns for follow-up complaining of excessive daytime sleepiness and a 3 kg weight gain. Laboratory studies show fasting glucose 118 mg/dL (normal <100) and triglycerides 220 mg/dL (normal <150). Which receptor antagonism is most responsible for both her sedation and metabolic disturbances?
2. A 65-year-old man with treatment-resistant schizophrenia is started on quetiapine. His other medications include ketoconazole for a fungal infection. One week later, he presents to the emergency department with severe sedation and orthostatic hypotension. Which of the following best explains this presentation?
3. A 45-year-old woman with schizophrenia has been stable on quetiapine for 2 years. She now reports irregular menstrual periods and galactorrhea. Serum prolactin level is markedly elevated at 98 ng/mL (normal 3-27). Which of the following is the most appropriate next step?
Frequently asked questions
How does quetiapine work?
Quetiapine works by blocking serotonin 5-HT2A and dopamine D2 receptors in the brain, which helps reduce psychotic symptoms. It also blocks histamine H1 receptors (causing sedation) and α1-adrenergic receptors (causing blood pressure lowering). Its active metabolite norquetiapine inhibits norepinephrine reuptake, contributing to antidepressant effects in bipolar depression and major depressive disorder.
What are the main side effects of quetiapine?
The most common side effects are sedation, dizziness, orthostatic hypotension, dry mouth, and constipation. Quetiapine carries high risk for metabolic side effects including weight gain, elevated blood sugar (risk of diabetes), and high cholesterol. Other serious but less common effects include QTc prolongation, cataracts, neuroleptic malignant syndrome, and tardive dyskinesia. Unlike many antipsychotics, it rarely causes elevated prolactin or extrapyramidal symptoms.
Is quetiapine a controlled substance?
No, quetiapine is not a controlled substance and is not classified as a scheduled drug by the DEA. However, there have been reports of misuse in certain populations (such as prisons) where it is used for its sedative effects. It does not produce euphoria or dependence in the way that benzodiazepines or stimulants do, but abrupt discontinuation can cause withdrawal symptoms, so it should be tapered gradually when stopping.
Quetiapine vs risperidone—what is the difference?
Both are atypical antipsychotics, but they differ in side effect profiles. Quetiapine causes more sedation, weight gain, and metabolic problems but has much lower risk of extrapyramidal symptoms (EPS) and hyperprolactinemia compared to risperidone. Risperidone is more potent at D2 receptors, making it more effective for severe psychosis but with higher risk of EPS, prolactin elevation (causing sexual dysfunction and galactorrhea), and less sedation. Quetiapine is also approved for bipolar depression, while risperidone is not.
Why is quetiapine prescribed for sleep?
Quetiapine is often prescribed off-label at low doses (25-100 mg) for insomnia because of its strong antihistamine (H1) effects that cause sedation. However, this practice is not evidence-based for primary insomnia and is generally discouraged. Low-dose quetiapine still carries risks of metabolic syndrome, weight gain, and other adverse effects without proven long-term efficacy or safety for insomnia. Safer, evidence-based alternatives like cognitive behavioral therapy for insomnia or appropriate hypnotics should be considered first.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: N05AH04
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.